Radiation Therapy Improves Survival in Patients with Distant Metastatic Head and Neck Squamous Cell Carcinoma: A Retrospective Study
- PMID: 39781346
- PMCID: PMC11705048
- DOI: 10.7150/jca.105254
Radiation Therapy Improves Survival in Patients with Distant Metastatic Head and Neck Squamous Cell Carcinoma: A Retrospective Study
Abstract
Background: The role of radiation therapy in patients with distant metastatic squamous cell carcinoma of the head and neck (mHNSCC) is unclear. In this study, we compare the differences in survival among mHNSCC patients treated with chemotherapy plus radiotherapy (RT) vs. chemotherapy alone.
Materials and methods: This study included patients with distant mHNSCC recruited from 2 cohorts: The Surveillance, Epidemiology, and End Results (SEER [N=885]) database and a Chinese single-institution registry in Sun Yat-sen University Cancer Center (SYSUCC [N=60]). The SEER cohort included 600 patients received RT plus chemotherapy and 285 patients received chemotherapy alone; in the SYSUCC cohort, 40 patients received RT plus chemotherapy and 20 patients received chemotherapy alone were recruited. The period of data collection for the SEER study was from January 2010 to December 2015, and that for SYSUCC was from January 2010 to December 2020. The study's primary outcome was overall survival (OS), with disease-specific survival (DSS) as a secondary outcome.
Results: Of the 885 patients in the SEER cohort, the addition of RT to chemotherapy increased one-year OS from 46.6% to 56.0% compared with chemotherapy alone (P =0.009) and from 10.4% to 25.1% for three-year OS (P <0.001). Patients who received RT in addition to chemotherapy were also more likely to have better three-year DSS than those who received chemotherapy alone (28.9% vs. 14.0%, P<0.001). Similarly, in the SYSUCC cohort, patients who received chemotherapy plus RT had better three-year OS than chemotherapy alone (62.8% vs. 21.0%, P=0.003). The addition of RT to chemotherapy increased median OS among patients with mHNSCC from 10 months to 13 months in the SEER cohort and from 14 months to 29 months in the SYSUCC cohort.
Conclusion: Radiotherapy in addition to chemotherapy significantly improved OS and DSS in patients with mHNSCC.
Keywords: SEER program; distant metastasis; radiation therapy; squamous cell carcinoma of the head and neck; survival.
© The author(s).
Conflict of interest statement
Competing Interests: The authors have declared that no competing interest exists.
Figures





Similar articles
-
Locoregional treatment of primary tumor in synchronous metastatic head and neck squamous cell carcinomas.Acta Oncol. 2023 May;62(5):465-472. doi: 10.1080/0284186X.2023.2209266. Epub 2023 May 7. Acta Oncol. 2023. PMID: 37151099
-
Prognostic nomograms and risk-stratifying systems for predicting survival in patients with resected pT2-4aN0M0 esophageal carcinoma.J Thorac Dis. 2021 Apr;13(4):2363-2377. doi: 10.21037/jtd-20-3393. J Thorac Dis. 2021. PMID: 34012585 Free PMC article.
-
Real-world data of immunotherapy from China in recurrent or metastatic head and neck squamous cell carcinoma.Am J Otolaryngol. 2024 Jan-Feb;45(1):104065. doi: 10.1016/j.amjoto.2023.104065. Epub 2023 Oct 12. Am J Otolaryngol. 2024. PMID: 37879241
-
Utility of Surgery/Radiotherapy in Distant Metastatic Head and Neck Squamous Cell Carcinoma: A Population-Based Approach.Otolaryngol Head Neck Surg. 2016 May;154(5):868-74. doi: 10.1177/0194599815627637. Epub 2016 Feb 16. Otolaryngol Head Neck Surg. 2016. PMID: 26884368
-
Addition of chemotherapy to hyperfractionated radiotherapy in advanced head and neck cancer-a meta-analysis.Strahlenther Onkol. 2019 Dec;195(12):1041-1049. doi: 10.1007/s00066-019-01511-z. Epub 2019 Oct 4. Strahlenther Onkol. 2019. PMID: 31586229 Review. English.
References
-
- Ferlito A, Shaha AR, Silver CE, Rinaldo A, Mondin V. Incidence and sites of distant metastases from head and neck cancer. ORL J Otorhinolaryngol Relat Spec. 2001;63:202–7. - PubMed
-
- Vermorken JB, Specenier P. Optimal treatment for recurrent/metastatic head and neck cancer. Ann Oncol. 2010;21(Suppl 7):vii252–61. - PubMed
-
- Cramer JD, Burtness B, Le QT, Ferris RL. The changing therapeutic landscape of head and neck cancer. Nat Rev Clin Oncol. 2019;16:669–83. - PubMed
-
- Chin D, Boyle GM, Porceddu S, Theile DR, Parsons PG, Coman WB. Head and neck cancer: past, present and future. Expert Rev Anticancer Ther. 2006;6:1111–8. - PubMed
LinkOut - more resources
Full Text Sources